APP and amyloidosis: While recent studies indicate that complete blockage of BACE1 activity may be associated with certain undesirable side-effects (also see "Putative Non-APP BACE1 Substrates" section below), important data demonstrates that in specific AD Tg models, partial reduction of BACE1 levels may improve cognitive deficits and amyloid neuropathology including Aβ deposition.